{"id":"NCT00853099","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2011-05","completion":"2013-08","firstPosted":"2009-03-02","resultsPosted":"2012-11-27","lastUpdate":"2014-09-05"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7 Humira"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab 80 mg/40 mg","type":"EXPERIMENTAL"},{"label":"Adalimumab 160 mg/80 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).","primaryOutcome":{"measure":"Percentage of Participants With Clinical Remission at 8 Weeks","timeFrame":"Week 8","effectByArm":[{"arm":"Placebo","deltaMin":11.5,"sd":null},{"arm":"Adalimumab 80 mg/40 mg","deltaMin":13.8,"sd":null},{"arm":"Adalimumab 160 mg/80 mg","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":65,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":96},"commonTop":["NASOPHARYNGITIS","HEADACHE","IRON DEFICIENCY ANAEMIA","DENTAL CARIES","BACK PAIN"]}}